These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31424455)

  • 1. Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review.
    Lin KJ; Lengacher CA
    Oncol Nurs Forum; 2019 Sep; 46(5):E145-E158. PubMed ID: 31424455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review.
    Benetou DR; Stergianos E; Geropeppa M; Ntinopoulou E; Tzanni M; Pourtsidis A; Petropoulos AC; Georgakis MK; Tousoulis D; Petridou ET
    Hellenic J Cardiol; 2019; 60(3):152-164. PubMed ID: 30273645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
    Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
    Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Saganelidze K; Kavtaradze N
    Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
    Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
    Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
    Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
    Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.
    Cavarretta E; Mastroiacovo G; Lupieri A; Frati G; Peruzzi M
    Adv Exp Med Biol; 2017; 1000():103-129. PubMed ID: 29098619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late cardiac effect of anthracycline therapy in physically active breast cancer survivors - a prospective study.
    Nagy AC; GulAcsi-BArdos P; CserEp Z; Hangody L; Forster T
    Neoplasma; 2017; 64(1):92-100. PubMed ID: 27881009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of routine pretreatment evaluation of left ventricular ejection fraction in breast cancer patients receiving anthracyclines.
    Peddi P; Master SR; Dwary AD; Ravipati HP; Patel AH; Pasam A; Katikaneni PK; Shi R; Burton GV; Chu QD
    Breast J; 2019 Jan; 25(1):62-68. PubMed ID: 30592128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
    Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
    Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-related cardiotoxicity in childhood cancer survivors.
    Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
    Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis.
    Pereira JD; Tosatti JAG; Simões R; Luizon MR; Gomes KB; Alves MT
    Biomed Pharmacother; 2020 Nov; 131():110709. PubMed ID: 32937248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
    Armenian SH
    Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
    Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
    Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.